Neuroprotective Properties of Bis-Sulfonamide Derivatives Against 6-OHDA-Induced Parkinson's Model via Sirtuin 1 Activity and in silico Pharmacokinetic Properties

Parkinson's disease (PD) is considered one of the health problems in the aging society. Due to the limitations of currently available drugs in preventing disease progression, the discovery of novel neuroprotective agents has been challenged. Sulfonamide and its derivatives were reported for several biological activities. Herein, a series of 17 bis-sulfonamide derivatives were initially tested for their neuroprotective potential and cytotoxicity against the 6-hydroxydopamine (6-OHDA)-induced neuronal death in SH-SY5Y cells. Subsequently, six compounds (i.e., 2, 4, 11, 14, 15, and 17) were selected for investigations on underlying mechanisms. The data demonstrated that the pretreatment of selected compounds (5 μM) can significantly restore the level of cell viability, protect against mitochondrial membrane dysfunction, decrease the activity of lactate dehydrogenase (LDH), decrease the intracellular oxidative stress, and enhance the activity of NAD-dependent deacetylase sirtuin-1 (SIRT1). Molecular docking was also performed to support that these compounds could act as SIRT1 activators. In addition, in silico pharmacokinetic and toxicity profile prediction was also conducted for guiding the potential development. Thus, the six neuroprotective bis-sulfonamides were highlighted as potential agents to be further developed for PD management.

[1]  Dokyun Na,et al.  In silico methods and tools for drug discovery , 2021, Comput. Biol. Medicine.

[2]  C. Nantasenamat,et al.  Mechanisms and Neuroprotective Activities of Stigmasterol Against Oxidative Stress-Induced Neuronal Cell Death via Sirtuin Family , 2021, Frontiers in Nutrition.

[3]  Jhimli Bhattacharyya,et al.  Sulfonamide drugs: structure, antibacterial property, toxicity, and biophysical interactions , 2021, Biophysical Reviews.

[4]  Hulya Akıncıoğlu,et al.  Synthesis of novel sulfonamides with anti‐Alzheimer and antioxidant capacities , 2021, Archiv der Pharmazie.

[5]  V. Prachayasittikul,et al.  Synthesis and neuroprotective effects of novel chalcone-triazole hybrids. , 2020, Bioorganic chemistry.

[6]  M. Cha,et al.  Neuroprotective Effect of Antioxidants in the Brain , 2020, International journal of molecular sciences.

[7]  J. Weber,et al.  The Pathology of Parkinson’s Disease and Potential Benefit of Dietary Polyphenols , 2020, Molecules.

[8]  Xiaoqing Wang,et al.  Computational Approaches in Preclinical Studies on Drug Discovery and Development , 2020, Frontiers in Chemistry.

[9]  B. Natarajan,et al.  Synthesis of caffeic acid sulfonamide derivatives and their protective effect against H2O2 induced oxidative damage in A549 cells , 2020, RSC advances.

[10]  P. Klivényi,et al.  Neuroprotection in Parkinson’s disease: facts and hopes , 2019, Journal of Neural Transmission.

[11]  M. Török,et al.  Sulfonamide derivatives as multi-target agents for complex diseases. , 2019, Bioorganic & medicinal chemistry letters.

[12]  V. Prachayasittikul,et al.  Synthesis, molecular docking, and QSAR study of bis-sulfonamide derivatives as potential aromatase inhibitors. , 2019, Bioorganic & medicinal chemistry.

[13]  G. Cenini,et al.  Oxidative Stress in Neurodegenerative Diseases: From a Mitochondrial Point of View , 2019, Oxidative medicine and cellular longevity.

[14]  B. Bloem,et al.  The Emerging Evidence of the Parkinson Pandemic , 2018, Journal of Parkinson's disease.

[15]  M. Perez-Pinzon,et al.  Brain SIRT1 Mediates Metabolic Homeostasis and Neuroprotection , 2018, Front. Endocrinol..

[16]  Dusti A. Shay,et al.  Cognitive Effects of Aromatase and Possible Role in Memory Disorders , 2018, Front. Endocrinol..

[17]  U. Kilic,et al.  High Levels of SIRT1 Expression as a Protective Mechanism Against Disease-Related Conditions , 2018, Front. Endocrinol..

[18]  G. Volcheck,et al.  Sulfonamide Drug Allergy , 2018, Current Allergy and Asthma Reports.

[19]  Ronald C Petersen,et al.  Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives. , 2018, The Journal of clinical investigation.

[20]  V. Prachayasittikul,et al.  Neuroprotective Effects of Phenolic and Carboxylic Acids on Oxidative Stress-Induced Toxicity in Human Neuroblastoma SH-SY5Y Cells , 2018, Neurochemical Research.

[21]  D. Hernandez-Baltazar,et al.  The 6-hydroxydopamine model and parkinsonian pathophysiology: Novel findings in an older model. , 2017, Neurologia.

[22]  Alzheimer’s Association.  2017 Alzheimer's disease facts and figures , 2017, Alzheimer's & Dementia.

[23]  Judith Jones,et al.  The aging population: demographics and the biology of aging. , 2016, Periodontology 2000.

[24]  M. Beal,et al.  Mitochondrial dysfunction in Parkinson's disease , 2016, Journal of neurochemistry.

[25]  Sumit Sarkar,et al.  Neuroprotective and Therapeutic Strategies against Parkinson’s Disease: Recent Perspectives , 2016, International journal of molecular sciences.

[26]  Ch Lai,et al.  Hydrogen-rich water attenuates amyloid β-induced cytotoxicity through upregulation of Sirt1-FoxO3a by stimulation of AMP-activated protein kinase in SK-N-MC cells. , 2015, Chemico-biological interactions.

[27]  A. Lang,et al.  Parkinson's disease , 2015, The Lancet.

[28]  Hualiang Jiang,et al.  Structural basis for allosteric, substrate-dependent stimulation of SIRT1 activity by resveratrol , 2015, Genes & development.

[29]  M. Ren,et al.  Dimethyl fumarate attenuates 6-OHDA-induced neurotoxicity in SH-SY5Y cells and in animal model of Parkinson’s disease by enhancing Nrf2 activity , 2015, Neuroscience.

[30]  I. Gülçin,et al.  Synthesis, Antioxidant, and Antiacetylcholinesterase Activities of Sulfonamide Derivatives of Dopamine‐Related Compounds , 2013, Archiv der Pharmazie.

[31]  M. Monsalve,et al.  SirT1 regulation of antioxidant genes is dependent on the formation of a FoxO3a/PGC-1α complex. , 2013, Antioxidants & redox signaling.

[32]  O. Hwang.  Role of Oxidative Stress in Parkinson's Disease , 2013, Experimental neurobiology.

[33]  Judith A. Potashkin,et al.  The Promise of Neuroprotective Agents in Parkinson’s Disease , 2011, Front. Neur..

[34]  J. Martinou,et al.  Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. , 2011, Developmental cell.

[35]  S. Rahman,et al.  Mammalian Sirt1: insights on its biological functions , 2011, Cell Communication and Signaling.

[36]  S. Mustafa,et al.  Synthesis, Structure Analysis and Antibacterial Activity of New Potent Sulfonamide Derivatives , 2011 .

[37]  G. Pasinetti,et al.  The role of Sirt1: at the crossroad between promotion of longevity and protection against Alzheimer's disease neuropathology. , 2010, Biochimica et biophysica acta.

[38]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[39]  A. Letai,et al.  Control of mitochondrial apoptosis by the Bcl-2 family , 2009, Journal of Cell Science.

[40]  Jau-Shyong Hong,et al.  Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. , 2008, Trends in immunology.

[41]  T. Lynch,et al.  The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. , 2007, American family physician.

[42]  N. Wood,et al.  Understanding the molecular causes of Parkinson's disease. , 2006, Trends in molecular medicine.

[43]  M. Breteler,et al.  Epidemiology of Parkinson's disease , 2006, The Lancet Neurology.

[44]  D. Prou,et al.  Toxin-induced models of Parkinson’s disease , 2005, NeuroRX.

[45]  Brian C. Smith,et al.  Mechanism of Human SIRT1 Activation by Resveratrol* , 2005, Journal of Biological Chemistry.

[46]  C. Supuran,et al.  Protease inhibitors of the sulfonamide type: Anticancer, antiinflammatory, and antiviral agents , 2003, Medicinal research reviews.

[47]  J. Labandeira-Garcia,et al.  Autoxidation and Neurotoxicity of 6‐Hydroxydopamine in the Presence of Some Antioxidants , 2000, Journal of neurochemistry.

[48]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[49]  H. Hurtig.  Problems with Current Pharmacologic Treatment of Parkinson's Disease , 1997, Experimental Neurology.

[50]  K. Lange,et al.  Pathogenesis of Parkinson's disease. , 1992, Current opinion in neurology and neurosurgery.

[51]  Menghang Xia,et al.  High-Throughput Screening Assays in Toxicology , 2016, Methods in Molecular Biology.

[52]  Francisca Cisneros Farrar,et al.  Aging population , 1999 .

[53]  Matsunami,et al.  Biological Activity , 2014 .

[54]  C. Haass,et al.  Mitochondrial dysfunction in Parkinson's disease. , 2010, Biochimica et biophysica acta.

[55]  G. Scambia,et al.  Assay for apoptosis using the mitochondrial probes, Rhodamine123 and 10-N-nonyl acridine orange , 2007, Nature Protocols.

[56]  F. Bricaire,et al.  Neurodegenerative diseases and oxidative stress. , 2004, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[57]  G. Choquet-Kastylevsky,et al.  Allergic adverse reactions to sulfonamides , 2002, Current allergy and asthma reports.

[58]  M. Beal,et al.  Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. , 2000, Journal of neural transmission. Supplementum.

[59]  M. Youdim,et al.  Mechanism of 6-hydroxydopamine neurotoxicity. , 1997, Journal of neural transmission. Supplementum.